A Deadline is coming up on April 17, 2017in the lawsuit for investors in Anthera Pharmaceuticals Inc and NASDAQ:ANTH stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 04/07/2017 -- A deadline is coming up on April 17, 2017 in the lawsuit filed for investors of Anthera Pharmaceuticals Inc (NASDAQ:ANTH over alleged securities laws violations by Anthera Pharmaceuticals Inc.
Investors who purchased shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) have certain options and there are strict and short deadlines running. Deadline: April 17, 2017. NASDAQ:ANTH stockholders should contact the Shareholders Foundation at firstname.lastname@example.org or call 858-779-1554.
According to the complaint filed in the U.S. District Court for the Northern District of California the plaintiff alleges on behalf of certain purchasers of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) common shares, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that Anthera Pharmaceuticals Inc made materially false and/or misleading statements concerning the potential efficacy and success of its Solution Study and CHABLIS-SC1 clinical trials, as the Company failed to disclose that patients were not improving in the CHABLIS-SC1 clinical trial, and that there were dosing problems inherent in the Solution Study design that created challenges to obtaining responses.
Hayward, CA based Anthera Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune disease. Shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) reached in 2015 as high as $10.91 per share.
On November 10, 2016, Anthera Pharmaceuticals Inc announced that "the CHABLIS-SC1 clinical trial with blisibimod for the treatment of systemic lupus erythematosus (SLE) failed to meet its primary endpoint based upon the SLE Responder Index-6 (SRI-6) at 52 weeks."
On December 27, 2016, Anthera Pharmaceuticals Inc announced that its SOLUTION Phase 3 Study for liprotamase also failed to meet its primary endpoint. The Company announced it would conduct a new study of liprotamase.
Shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) declined to as low as $0.64 per share on December 30, 2016.
Those who purchased shares of Anthera Pharmaceuticals Inc have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego